Skip to Main Content
Contribute Try STAT+ Today

AstraZeneca (AZN) said Monday that it would stop a large clinical study of a fish-oil-derived heart drug, Epanova, after an independent committee concluded it was “unlikely to demonstrate a benefit to patients.”

The news removes the most likely competitor for Vascepa, the first heart drug derived from fish oil to be approved to reduce the risk of heart attacks, strokes, and hospitalizations due to heart problems in patients with high levels of triglycerides. Vascepa is the only product sold by Amarin Pharmaceuticals (AMRN), which has said it expects sales of more than $650 million next year, a 50% annual increase.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.